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Abstract: Conventional chemotherapy of ovarian cancer often fails because of initiation of drug 
resistance and/or side effects and trace of untouched remaining cancerous cells. This highlights an 
urgent need for advanced targeted therapies for effective remediation of the disease using a cyto-
toxic agent with immunomodulatory effects, such as shikonin (SHK). Based on preliminary experi-
ments, we found SHK to be profoundly toxic in ovarian epithelial cancer cells (OVCAR-5 and 
ID8 cells) as well as in normal ovarian IOSE-398 cells, endothelial MS1 cells, and  lymphocytes. 
To limit its cytotoxic impact solely to tumor cells within the tumor microenvironment (TME), we 
aimed to engineer SHK as polymeric nanoparticles (NPs) with targeting moiety toward tumor 
 microvasculature. To this end, using single/double emulsion solvent evaporation/ diffusion tech-
nique with sonication, we formulated biodegradable NPs of poly(lactic-co-glycolic acid) (PLGA) 
loaded with SHK. The surface of NPs was further decorated with solubilizing agent polyethylene 
glycol (PEG) and tumor endothelial marker 1 (TEM1)/endosialin-targeting antibody (Ab) through 
carbodiimide/N-hydroxysuccinimide chemistry. Having characterized the physicochemical and 
morphological properties of NPs, we studied their drug-release profiles using various kinetic 
models. The biological impact of NPs was also evaluated in tumor-associated endothelial MS1 
cells, primary lymphocytes, and epithelial ovarian cancer OVCAR-5 cells. Based on particle size 
analysis and electron microscopy, the engineered NPs showed a smooth spherical shape with size 
range of 120 to 250 nm and zeta potential value of −30 to −40 mV. Drug entrapment efficiency was 
∼80%–90%, which was reduced to ∼50%–60% upon surface decoration with PEG and Ab. The 
liberation of SHK from NPs showed a sustained-release profile that was best fitted with Wagner 
log-probability model. Fluorescence microscopy and flow cytometry analysis showed active 
interaction of Ab-armed NPs with TEM1-positive MS1 cells, but not with TEM1-negative MS1 
cells. While exposure of the PEGylated NPs for 2 hours was not toxic to lymphocytes, long-term 
exposure of the Ab-armed and PEGylated NPs was significantly toxic to TEM1-positive MS1 
cells and OVCAR-5 cells. Based on these findings, we propose SHK-loaded Ab-armed PEGylated 
PLGA NPs as a novel nanomedicine for targeted therapy of solid tumors.
Keywords: nanomedicine, nanoparticle, ovarian cancer, shikonin, targeted therapy, tumor 
vasculature
Introduction
The survival rate of ovarian cancer patients is often low, particularly in patients with 
recurrent malignancies. After conventional chemotherapy, high percentages of patients 
are inevitably prone to profound toxicity in normal cells/tissue and drug resistance.1–3 
Further, the malignancy may relapse, complicating the second course of chemotherapy; 
advanced nanomedicines have been shown to be more effective than conventional 
chemotherapy.4,5 Battles with cancer can be substantially improved if cytotoxicity is 
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combined with anticancer immunosurveillance. This can be 
accomplished by implementing advanced innocuous nano-
medicines with the ability to deliver cytotoxic and immuno-
modulatory agents to the tumor microenvironment (TME), 
induce toxic impacts solely within the cancerous cells, and 
activate the immune system.
Of various anticancer agents, very few show such 
 characteristics; however, among numerous natural products 
examined for anticancer and immunomodulatory effects, 
shikonin (SHK) and alkannin derivatives (R-enantiomer and 
S-enantiomer, respectively) appear to provide such phar-
macological effects.6–9 SHK- and alkannin-derivatives have 
previously been produced through bioprocess  engineering of 
Echium italicum L,10,11 and these compounds showed substan-
tial inhibitory effects in various cancerous cell lines (Barar 
et al, unpublished data, 2014). Despite having immunomodu-
latory effects,9 SHK, as a highly liposoluble naphthoquinone 
pigment, can inhibit pyruvate kinase M2 activity,12,13 upregu-
late p53 activity and downregulate cyclin-dependent protein 
kinase 4 activity,14 upregulate BCL2-associated X protein 
(BAX) and downregulate B-cell lymphoma 2 (BCL2),6 and 
inhibit extracellular signal-regulated kinases (ERK) and 
protein kinase B pathways.15 All these studies confirm that 
SHK can induce significant cytotoxicity, while its cytotoxic 
impacts are not specific to cancer cells. Hence, like any other 
cytotoxic agent, SHK needs to be delivered solely to the 
cancer cells, preferably using targeted nanomedicines.
Smart targeted nanoparticles (NPs) have been shown 
to accumulate within the TME through both passive (ie, 
enhanced permeation and retention [EPR] effect) and 
active (ie, targeting a cancer marker molecule) mechanisms, 
resulting in enhanced effects, mainly in cancerous cells.16–18 
Given the fact that biodegradable polymeric NPs elicit 
negligible side effects, they have been widely investigated 
for efficient and safe delivery of encapsulated/entrapped 
chemotherapeutics to the target cells.17 Of these, poly(lactic-
co-glycolic acid) (PLGA) is the most studied polymer;19–21 
it is also a safe biocompatible polymer in comparison with 
 synthetic polymers/lipids used as delivery systems.22–24 PLGA 
polymer has previously been used for delivery of insulin21 and 
doxorubicin (Adriamycin).19 In the current work, we aimed 
to engineer SHK-loaded, surface-modified PLGA NPs (eg, 
SHK-loaded, polyethylene glycol [PEG]ylated, and antitumor 
endothelial marker 1 [TEM1] antibody [Ab]/single-chain 
variable fragment [scFv]-armed PLGA NPs) and investigate 
their biological effects in tumor endothelial TEM1-positive 
MS1 cells, TEM1-negative MS1 cells, epithelial (OVCAR-5 
and ID8) cells, and primary isolated lymphocytes.
Materials and methods
Materials
SHK, fluorescein (FSN), Tween 80, Pluronic® F-68, NH
2
-
PEG
3000
-COOH, NH
2
-PEG
3000
-OH, sulforhodamine B (SRB), 
2-(N-morpholino)ethanesulfonic acid (MES), ethylenedi-
aminetetraacetic acid (EDTA), 4′,6-diamidino-2-phenylindole 
(DAPI), phalloidin– tetramethylrhodamine B isothiocyanate 
 (phalloidin-TRITC), acid-terminated (50:50) poly(D,L- lactide-
co-glycolide) (24,000–38,000 and 38,000–54,000 Mw), 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochlo-
ride (EDC), N- hydroxysulfosuccinimide sodium salt (NHS), 
dichloromethane, chloroform, dimethyl sulfoxide, O-(2-
 aminoethyl)PEG 3000, N,N-diisopropylethylamine p-toluene-
sulfonate salt, methoxypolyethylene glycol amine, polyvinyl 
alcohol (Mowiol® 4-88), Trypan Blue, Triton™ X-100, and 
staurosporine were purchased from Sigma-Aldrich (St Louis, 
MO, USA). Roswell Park Memorial Institute medium (RPMI) 
1640  (GlutaMAX™), fetal bovine serum, penicillin G, strepto-
mycin, Dulbecco’s Modified Eagle’s Medium, and L- glutamine 
were purchased from Invitrogen (Life  Technologies,  Carlsbad, 
CA, USA). All cell lines were from American Type Culture 
Collection (ATCC)  (Manassas, VA, USA) and human TEM1-
positive MS1 cells were developed in our laboratory as reported 
previously.25 All tissue culture dishes and Coomassie dye were 
purchased from Thermo Fisher Scientific (Waltham, MA, USA). 
Anti-TEM1 (H-63) Ab was from Santa Cruz Biotechnology, 
Inc (Santa Cruz, CA, USA). Anti-TEM1 scFvs were produced 
in our laboratory (courtesy of Dr Aizhi Zhao). The secondary 
streptavidin-allophycocyanin (APC) tagged Ab and fixable 
viability dye eFluor 506 were purchased from eBioscience (San 
Diego, CA, USA).  Annexin V-EnzoGold was purchased from 
Enzo Life Sciences (Farmingdale, NY, USA). All other chemi-
cals not listed were purchased in the highest purity available.
Formulation of NPs
For formulation of PLGA NPs, we capitalized on a single 
emulsion-solvent evaporation technique. Briefly, SHK 
(15 mg/mL) and FSN (5 mg/mL) were dissolved in 3 mL 
of oil phase (chloroform or ethyl acetate) containing 3% 
PLGA and surfactant (either 2%–4% Pluronic F68 or 2%–5% 
polyvinyl alcohol). The oil phase was mixed with 10mL of the 
water phase (ie, double-distilled water containing 1% Tween 
80) over an ice bath under sonication at 40 W output for 
4 minutes (2×2 minutes) using a probe sonicator (VCX 130; 
Sonics and Materials, Inc, Newtown, CT, USA). Then, the oil 
phase was eliminated by evaporation under reduced pressure 
(150–200 mbar) using a rotary evaporator (30 rpm) (Hei-
VAP Advantage ML/G5B; Heidolph North America, Grove 
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Village, IL, USA). Drug-free PLGA NPs were formulated 
using the same procedure. The effects of formulation variables 
on the NP characteristics were examined. The formulated 
NPs were resuspended in 1 mL trehalose (250 mM), used as 
cryoprotectant (to prevent lyophilization-induced aggrega-
tion), supplemented with 0.5% Tween 80, and lyophilized 
for later use.
Particle size and zeta potential analyses
To determine the size and zeta potential of NPs, 1 mg/mL 
suspension of the formulated NPs was prepared in double-
distilled water. Then, 20 µL of each sample was diluted to 1 
mL and, after brief sonication, the size and zeta potential of 
the NPs were analyzed using a Zetasizer Nano-ZS (Malvern 
Instruments, Malvern, UK).
Transmission (TeM) and scanning  
(seM) electron microscopy
For morphological characterization, the formulated NPs were 
evaluated by TEM and SEM. For TEM analysis, a sample of 
NPs (0.5 mg/mL) was suspended in water and sonicated for 
30 seconds. One drop of this suspension was placed over a 
carbon-coated copper TEM grid (150–400 mesh; Ted Pella, 
Inc, Redding, CA, USA) and allowed to dry. Images were 
visualized at 120 KeV at indicated magnifications on a 
Tecnai 12 microscope (FEI, Hillsboro, OR, USA) equipped 
with a Gatan, Inc (Pleasanton, CA, USA) 896 2.2.1 US1000 
camera. For SEM analysis, PLGA NPs were applied to mica 
and allowed to air dry. Then, the samples were imaged at 
5–10 KeV on a JEOL JSM-7500F microscope (JEOL USA, 
Inc, Peabody, MA, USA) at designated magnifications. 
The NPs were sputtered with gold in order to improve their 
conductivity and placed on a copper stub before the acquisi-
tion of SEM images.
Drug content (Dc%), drug entrapment 
(De%), drug loading (Dl%), and yielding 
(YE%) efficiencies
Both SHK and FSN contents of the NPs were estimated by 
ultraviolet (UV) spectrophotometric method. Briefly, a desig-
nated amount of lyophilized SHK-loaded NPs was dissolved 
in acetonitrile (1 mg/mL) and kept on a shaker at 37°C for 
72 hours for complete release of the entrapped drug. Then, 
samples were removed and centrifuged at 10,000× g for 5 
minutes at 4°C to extract the drug present in the solution. The 
supernatant (700 µL) was collected, and the absorbance of 
the supernatant was measured by a UV spectrophotometer, 
(Genesys 6; Thermo Fisher Scientific) at a wavelength of 
520 nm. As shown in Table 1, we calculated DC%, DE%, 
DL%, and yielding efficiency (YE%) for all formulations.
release kinetics analysis
In vitro release kinetics of SHK from PLGA NPs was deter-
mined using phosphate-buffered saline (PBS) release  buffer 
(137 mM NaCl, 2.7 mM KCl, 4.3 mM Na
2
HPO
4
, 1.47 mM 
KH
2
PO
4
) at various pHs (pH 4.4, 5.4, 6.4, and 7.4) at 37°C. 
The NPs (25 mg) were dispersed in 5 mL of the PBS buffer 
and divided into equal aliquots (1 mL each). These tubes were 
kept on a shaker at 37°C and 150 rpm. At designated time 
intervals (1, 2, 4, 8, 12, 24, 48, and 72 hours), these tubes 
were taken from the shaker and centrifuged at 9,000× g at 
4°C for 5 minutes. Then, the supernatant was removed to 
estimate the amount of released drug using the Genesys 6 
UV spectrophotometer, at a wavelength of 520 nm (SHK) and 
Table 1 DC%, DE%, DL%, and process YE% of shikonin-loaded NPs before and after modification
Formulation characteristics Plain NPs PEGylated NPs Ab-armed NPs
Dc% 100=
−
×
D mass D mass
NP mass
t f



12.8 10.4 7.5
De% 100= ×




D mass D mass
D mass
t f
t
− 87.0 65.0 42.0
Dl% 100=
−
×    
D mass D mass
P mass
t f
t




14.0 11.8 8.6
Ye% 100=
+
×
NP mass
D mass Pt t




85.0 75.0 60.0
Abbreviations: Ab, antibody; DC%, drug content efficiency; DE%, drug entrapment efficiency; Df, free drug; DL%, drug loading efficiency; Dt, total drug; NP, nanoparticle; 
Peg, polyethylene glycol; Pt, total polymer; YE%, yielding efficiency.
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490 nm (FSN). The release data were analyzed using various 
kinetics models (Table 2), as described previously.26
Pegylation and ab conjugation
We implemented one-/two-step PEGylation and Ab conju-
gation approaches for surface modifications.27 For one-step 
PEGylation and Ab conjugation, a designated amount (10 mg) 
of acid-terminated PLGA NPs was resuspended in 2–4 mL 
MES (pH 6) and activated with 250 µL EDC (1 mg/mL) and 
250 µL NHS (1 mg/mL) for 2 hours at room temperature. 
After washing with 50 mM sucrose, pH 8 (2×) by centrifu-
gation at 8,500× g (4°C) for 5 minutes, the activated NPs 
were resuspended in PBS and incubated with 250 µL NH
2
-
PEG
3000
-OH and 100 µL Ab (at a final molar ratio of 10:1) for 
2 hours at room temperature (or at 4°C overnight). For two-
step conjugation, the same process was performed separately 
for each of PEGylation and Ab conjugation (PEG:Ab/ScFv 
ratio 10:1). The modified NPs were washed twice using 50 
mM sucrose (pH 8) by centrifugation at 8,500× g (4°C) for 
5 minutes to remove the unconjugated molecules. The super-
natant was collected to calculate the conjugation efficiency 
using UV  spectrophotometry analysis, and the NPs were 
lyophilized for further studies. Figure 1 shows a schematic 
representation of PEGylation and Ab conjugation.
Determination of ab  
conjugation efficiency
For conjugation efficiency, Bradford method, using  Coomassie 
dye, was employed. Briefly, 300 µL of  Coomassie plus reagent 
was added to Ab-conjugated NPs (10 mg  dispersed NPs in 
200 µL PBS pH 7.4) and incubated for 10–15 minutes. Then, 
the absorbance was measured at 595 nm using a microplate 
reader (EL800; BioTek, Winooski, VT, USA). The results were 
compared to a standard curve of bovine serum albumin (BSA) 
solution using a designated concentration range (10 µg/mL to 
1,000 µg/mL).
cell culture
Cell lines were cultured onto well-plates using RPMI 1640 
(GlutaMAX™) supplemented with 10% fetal bovine serum, 
100 units/mL penicillin G, and 100 µg/mL streptomycin. 
Lymphocytes were further supplemented with 20 U/mL of 
interleukin (IL)-2.
The cultured cells were kept in a humidified incubator 
with 5% CO
2
 at 37°C during cultivation and  experiments. 
The primary lymphocyte isolation was performed by the 
Human Immunology Core (HIC) facility at the University of 
Pennsylvania, Philadelphia, PA, USA. The lymphocytes were 
kept in 24-well plates at a seeding density of 5×105 cells/well 
Table 2 The kinetics models used to fit the release data
Kinetics model Equation Coefficient of determination (R2)
pH 4.4 pH 5.4 pH 6.4 pH 7.4
Zero order F k t=
0
0.777 0.788 0.762 0.728
First order Ln(1 F) k t
f
− = − 0.901 0.922 0.915 0.945
higuchi
F k t
H
=
0.918 0.926 0.910 0.884
Power law LnF Lnk pLnt
p
= + 0.927 0.933 0.915 0.910
square root of mass
1 1 F k t
1/2
− − =
0.652 0.650 0.608 0.520
hixson–crowell
1 1 F k t3
1/3
− − =
0.805 0.820 0.799 0.796
Three seconds root 
of mass 1 (1 F) k t
3
2/3
− − =
2
0.710 0.723 0.693 0.663
Weibull Ln Ln(1 F) Ln t Ln td[ ]− − = − +β β
0.961 0.970 0.960 0.974
linear probability Z Z qt= +0
0.778 0.790 0.763 0.727
Wagner log-probability Z Z q Lnt
0
′ = ′ + ′ 0.997 0.998 0.997 0.993
Notes: Parameters of models were obtained by linear regression. F represents fraction of drug released up to time t. The k0, kf, kH, p, kP, k1/3,k1/2, k2/3, td, β, Z0, Z0′ , q, and q′ are 
parameters of the models. Z and Z′ denote probits of fraction of drug released at any time. ln: natural logarithm. 
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and 20 U/mL of IL-2 was supplemented in the media to help 
their proliferation before the assay.
Fluorescence microscopy
Fluorescence microscopy was used for evaluation of the 
 cellular interaction of SHK-loaded PLGA NPs and the 
 cellular impact of free SHK.
For the cellular interaction of SHK-loaded PLGA NPs 
armed with anti-TEM1 Ab/scFv, briefly, TEM1-positive and 
TEM1-negative MS1 cells were seeded onto the coverslip 
and, at 40%–50% confluency, were treated with a designated 
amount of NPs for 1–2 hours. The cellular association/
interaction of NPs was terminated by transferring the plate 
onto ice. Then, cells were washed four times with ice-cold 
PBS (1x) to remove any NP remains and concurrently 
fixed and permeabilized (using 4% paraformaldehyde with 
0.1% Triton™ X-100 prepared in PBS) for 20 minutes at 
room temperature. After washing three times with PBS, the 
nonspecific binding sites were blocked with 1% BSA pre-
pared in PBS for 30 minutes’ incubation at room temperature. 
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Figure 1 schematic illustration of Pegylation and antibody conjugation.
Notes: (A) activation of acid-terminated Plga NPs by eDc and Nhs. (B) One-step Pegylation and antibody conjugation. (C) Two-step Pegylation and antibody conjugation.
Abbreviations: ab, antibody; eDc, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride; FSN, fluorescein; NHS, N-hydroxysulfosuccinimide sodium salt; 
NP, nanoparticle; Peg, polyethylene glycol; Plga, poly(lactic-co-glycolic acid); shK, shikonin; scFv, single-chain variable fragment.
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After removal of BSA and washing three times with PBS, 
the cells were stained with phalloidin-TRITC solution for 
40 minutes at room temperature then washed three times 
with PBS, and the nucleus was stained by DAPI. The cov-
erslips were inverted onto microscope slides and sealed 
with nail polish. Cell morphology and characteristics were 
monitored using a fluorescence microscope (ECLIPSE Ti; 
Nikon  Corporation, Tokyo, Japan) equipped with a charge-
coupled device camera (Photometrics CoolSnap HQ2; Roper 
Industries, Inc, Sarasota, FL, USA) and NIS-Elements AR 
software (v 3.2; Nikon Corporation).
A similar approach was undertaken to examine the 
 morphological changes of the OVCAR-5 cells treated with 
free SHK or SHK-loaded NPs. For the cellular impact of free 
SHK, the cultivated cells in coverslip, at 40%–50% conflu-
ency, were treated with a designated amount of free SHK (5.0, 
10.0, or 20.0 µM). After 24 hours, the cells were subjected to 
the fluorescence microscopy analysis as described above.
cell migration assay
To address the impacts of SHK on cell proliferation and migra-
tion, we used a simple cell scratch assay. Briefly, the confluent 
OVCAR-5 cells cultivated in six-well plates were scraped in a 
straight line to create a  scratch in the middle of the well using 
a 200 µL pipette tip. After washing four times with PBS, the 
scratched cells were exposed to designated concentrations of 
free SHK or SHK-loaded NPs. The morphological changes over 
a designated time period were evaluated using an ECLIPSE Ti 
light microscope for 16 hours post-treatment.
cytotoxicity evaluation
The bioactivity of free SHK and SHK-loaded PLGA NPs 
was evaluated by SRB assay, as described previously.28 
Briefly, cells were cultured at a seeding density of 3.0×104 
cells/cm2 onto 96-well plates. After 24 hours, the cells were 
treated with designated concentrations of SHK or equivalent 
SHK-loaded NPs for 24 and 48 hours. To study the impact of 
targeting moiety on cytotoxicity, the treatments were removed 
after 2 hours of initial exposure and then cells were allowed 
to grow for 24 or 48 hours. At the end of incubation, the 
treated cells were fixed using 10% trichloroacetic acid for 
60 minutes at 4°C. After washing four times with water, the 
plates were left to dry and then stained with SRB staining 
solution (0.057% w/v in 1% v/v acetic acid solution) for 
30 minutes at room temperature. The cells were washed four 
times with 1% acetic acid solution. After drying, the cells 
were solubilized with 200 µL of 10 mM Tris base solution 
(pH 10.5) on a shaker for 30 minutes. The absorbance was 
measured using an EL800 microplate reader at 570 nm. 
The cell viability was calculated as percentage of untreated 
control cells. Trypan Blue exclusion assay was used to 
assess the cytotoxicity potential of SHK-loaded PLGA NPs 
in Jurkat cell line.
Flow cytometry analysis
To detect any transition from apoptosis to necrosis, we imple-
mented the flow cytometry assay using phospholipid-binding 
annexin V protein, which binds to phosphatidylserine with 
a high affinity in the presence of Ca2+ and is considered the 
main sign for occurrence of early apoptosis.29 Briefly, the 
cultivated cells in a six-well plate were treated with various 
concentrations of SHK (as free drug or NP formulation). 
Twelve hours post-treatment, the treated and untreated cells 
were gently trypsinized and centrifuged at 200× g for 5 min-
utes. Then, 1.0×106 cells were washed with 5.0 mL ice-cold 
PBS by centrifugation at 200× g for 5 minutes and resus-
pended in 500 µL of binding buffer (1x), containing 5 µL of 
apoptosis detection reagent (Annexin V-EnzoGold) and 5 µL 
of necrosis detection reagent, and incubated for 15 minutes at 
room temperature. The samples were then analyzed by flow 
cytometry using the FL2  channel for the apoptosis detec-
tion reagent and the FL3 channel for the necrosis detection 
reagent. The treated samples were compared with the positive 
control cells (ie, by UV irradiation for 15 minutes for MS1 
cells and for 30 minutes for OVCAR-5) and the untreated 
control cells. Flow cyto metry assay was also performed to 
study the internalization of Ab-/scFv-armed NPs by TEM1-
positive MS1 cells and TEM1-negative MS1 cells. For uptake 
study, cells were treated with free SHK or SHK-loaded NPs 
for 2 hours, and then the plates were transferred onto ice 
and the internalization of NPs was analyzed. Besides, the 
expression of TEM1 in MS1 cells was also validated and 
quantified by flow cytometry analysis.
DNa fragmentation analysis
DNA fragmentation analysis was performed in the ovarian 
cancer OVCAR-5 cells. For DNA fragmentation, cells were 
cultured overnight and then treated with different concen-
trations of SHK. After 24 hours, the cells were trypsinized 
and 2.0×106 cells were resuspended in 500 µL Tris–EDTA 
buffer (10 mM Tris-HCl pH 7.4, 1 mM EDTA) containing 
0.2% Triton™ X-100. After vortexing for 1 minute, 100 µL 
of ice-cold 5M NaCl was added to the sample, which was 
vortexed for a further 1 minute to remove the DNA from 
associated proteins. Then, 700 µL of ice-cold isopropanol 
was added to the sample, which was vortexed for 1 minute 
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and kept overnight at −20°C. DNA was then recovered by 
centrifugation at 16,000× g at 4°C for 10 minutes. DNA pel-
lets were washed twice with 700 µL ice-cold 85% ethanol 
by centrifugation at 16,000× g at 4°C for 10 minutes. Then, 
150 µL of Tris–EDTA buffer was added to each sample and 
the samples incubated at 37°C overnight. DNA samples were 
then mixed with loading buffer and incubated at 65°C for 
10 minutes prior to electrophoresis using 1.2% agarose gel 
containing ethidium bromide (0.5 mg/mL) and Tris–acetate–
EDTA buffer (1x) and visualized using a gel documentation 
system.
statistical analysis
Data were statistically analyzed using t-test or one-way 
analysis of variance. A P-value less than 0.05 was used to 
show statistical significance. 
Results
size, zeta potential,  
and morphology analyses
Based upon formulation methods and components, the size 
of the engineered PLGA NPs varied from 120 to 250 nm. 
Figure 2 represents the size distribution and zeta potential 
of the engineered PLGA NPs.
The zeta potential of SHK-loaded NPs was approxi-
mately −35 mV. The TEM and SEM micrographs displayed 
the engineered PLGA NPs with a spherical shape and smooth 
surface. Figure 3 represents the TEM and SEM micrographs 
of the SHK-loaded PLGA NPs.
De% and release kinetics
Table 1 shows the DC%, DE%, DL%, and YE% of SHK-
loaded NPs before and after modification. After PEGylation 
and Ab/scFv conjugation, these values were significantly 
reduced. FSN content was similar to SHK (data not shown).
Figure 4 demonstrates the release of SHK from PLGA 
NPs. Table 2 represents various kinetics models used to fit 
the SHK release profile. As shown in Table 2 and Figure 4 
(inset), SHK release profile was best fit with Wagner log-
probability. The pattern of drug liberation revealed that 20% 
of drug was released within the first 2 hours, while 80% of 
drug was released after 48 hours. The release of SHK from 
NPs appeared to be somewhat pH-dependent, with highest 
release at pH 7.4.
PEGylation and conjugation efficiency
After formulation, PLGA NPs were further solubilized 
through PEGylation and conjugated with either anti-TEM1 
Ab or scFv Ab fragment (Figure 1). One-step PEGylation 
and Ab conjugation resulted in NPs with higher drug con-
tent, while the PEGylation and Ab conjugation efficiency 
appeared to be somewhat variable. The drug content of the 
two-step PEGylation and Ab conjugation was lower than 
that of the one-step approach, while the PEGylation and Ab 
conjugation efficiency appeared to be consistent. Bradford 
Coomassie dye analysis revealed conjugation efficiency 
values of ∼15% and ∼20% for anti-TEM1 Ab and scFv Ab 
fragment, respectively.
Fluorescence microscopy
Figure 5 represents the active targeting of TEM1 by Ab-
armed PLGA NPs in TEM1-positive MS1 cells. Both Ab-
armed and scFv-armed PLGA NPs markedly interacted with 
the TEM1-positive MS1 cells, but not the TEM1-negative 
MS1 cells.
We designed Ab-armed PLGA NPs loaded with SHK 
to target tumor endothelial cells through TEM1 antigen, by 
which the NPs can be accumulated within the TME and taken 
up by epithelial ovarian cancer cells through both passive and 
active targeting mechanisms.
Figure 6 represents the fluorescence microscopy images 
of free SHK-treated OVCAR-5 cells. Marked morphological 
changes in cytoplasm together with shrinkage of nucleus 
were observed in the epithelial ovarian cancer OVCAR-5 
cells treated with free SHK in a dose-dependent manner. 
Both free SHK and SHK-loaded NPs imposed similar 
morphological changes in OVCAR-5 cells as well as in 
ID8 cells.
cell migration assay
Figure 7 represents the migration of OVCAR-5 cells in the 
presence of SHK at the concentrations of 0.5 µM (Figure 7C), 
2.5 µM (Figure 7D), and 5.0 µM (Figure 7E). The untreated 
cells (Figure 7B) managed to fill the gap within 6 hours 
post-scratching as compared to that of time 0 (Figure 7A); 
however, SHK significantly reduced the growth and migra-
tion of the treated cells: the higher the SHK concentration, 
the greater the inhibition of cell growth and migration 
(Figure 7F).
Interaction of ab-armed NPs  
with TeM1-positive Ms1 cells
To determine the specific binding of formulated NPs and 
targeting efficiency, the TEM1-positive MS1 cells were 
quantified using flow cytometry. Based on our flow cyto-
metry analysis, over 90% of the transfected MS1 cells showed 
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Figure 2 size distribution and zeta potential of Plga NPs.
Notes: (A) size and (B) zeta potential of unloaded Plga NPs. (C) size and (D) zeta potential of shikonin-loaded Plga NPs. red arrow represents diameter Z-average.
Abbreviations: NPs, nanoparticles; Plga, poly(lactic-co-glycolic acid).
TEM1 expression. Accordingly, the TEM1-positive MS1 cells 
showed significantly higher uptake of the Ab-/scFv-armed 
PLGA NPs compared to the TEM1-negative MS1 cells (data 
not shown).
cellular toxicity
To evaluate the cytotoxic effect of SHK, we first examined 
the toxicity impacts of the free SHK in the normal and can-
cerous cells using SRB assay. We observed that free SHK 
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Figure 3 TeM and seM micrographs of the shikonin-loaded Plga NPs.
Notes: (A) TeM image of Plga NPs. (B) Maximized TeM image of a single Plga 
NP. (C) Maximized seM image of a single Plga NP.
Abbreviations: NP, nanoparticle; Plga, poly(lactic-co-glycolic acid); seM, scanning 
electron microscopy; TeM, transmission electron microscopy.
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Note: The inset shows the release data fit with the Wagner log-probability.
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affected viability of normal ovarian IOSE-398 cells (Figure 
8A), Jurkat cells (Figure 8B), ovarian cancer ID8 cells (Figure 
8C), and OVCAR-5 cells (Figure 8D) in a concentration-
dependent manner. To avoid the nonspecific cytotoxic 
impacts of free SHK, we aimed at engineering SHK-loaded 
PEGylated PLGA NPs. Figure 9 represents the cytotoxic 
effects of free SHK, free PLGA NPs, SHK-loaded PLGA 
NPs, and SHK-loaded PEGylated PLGA NPs in primary 
T-cells. The PEGylation process significantly reduced the 
cytotoxic effects of SHK.
Next, the TEM1-positive MS1 cells and TEM1-negative 
MS1 cells were treated with Ab-/scFv-armed NPs and 
unarmed NPs loaded with SHK. Figure 10 represents the 
cytotoxic effects of Ab-/scFv-armed PEGylated PLGA NPs 
loaded with SHK 2.5 µM (Figure 10A) or 5 µM (Figure 
10B) in TEM1-positive MS1 cells and TEM1-negative MS1 
cells after 24 hours. Similar impacts were seen at 48 hours 
post-treatment (data not shown). The Ab-/scFv-armed PEGy-
lated PLGA NPs loaded with SHK induced significantly 
(P,0.05) greater cytotoxicity in TEM1-positive MS1 cells, 
but not in TEM1-negative MS1 cells.
To revalidate the SRB results and reveal the stage of 
apoptosis/necrosis, we further performed flow cytometry 
analysis. We found that free SHK or SHK-loaded NPs were 
able to induce necroptosis (a programmed necrosis) (Figure 
10C–F), while the scFv-armed PEGylated PLGA NPs loaded 
with SHK induced greater cytotoxicity in TEM1-positive 
MS1 cells (Figure 10F).
We assumed that the NPs could be accumulated 
within the TME through both passive and active targeting 
 mechanisms. Thus, to assess the final end point of the engi-
neered NPs, their cytotoxicity was examined in the ovarian 
epithelial OVCAR-5 cells. We witnessed that the growth 
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of the OVCAR-5 cells was significantly inhibited upon 
treatment with SHK in a dose-dependent manner. The cells 
treated with 10.0 µM SHK showed over 80% and 90% 
inhibition after 24 (Figure 11A) and 48 (Figure 11B) hours, 
respectively.
DNa fragmentation analyses
To evaluate the impact of SHK on DNA integrity, presented 
in Figure 12, we also performed DNA defragmentation 
analysis in OVCAR-5 cells treated with various concentra-
tions of SHK (2.5, 5.0, and 10.0 µM) for 24 hours. We found 
that SHK could induce significant DNA fragmentation in a 
dose-dependent manner.
Discussion
Ovarian cancer, as the most common type of gynecologic 
malignancy, is one of the leading causes of cancer deaths 
among women. After conventional chemotherapy, most ovar-
ian cancer patients show relapse and become drug resistant. 
Although cancer chemotherapy has been accepted as an effec-
tive treatment modality for ovarian cancer, this approach is 
often associated with inadvertent intrinsic side effects, mainly 
A
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Figure 5 Fluorescence and transmission light microscopy of anti-TEM1 Ab-/scFv-armed fluorescein- and shikonin-loaded PLGA NPs in endothelial MS1 cells.
Notes: (A) Untreated TeM1-negative Ms1 cells. (B) anti-TeM1 ab-armed NPs treated TeM1-negative Ms1 cells. (C) anti-TeM1 scFv-armed NPs treated TeM1-negative Ms1 
cells. (D) Untreated TeM1-positive Ms1 cells. (E) anti-TeM1 ab-armed NPs treated TeM1-positive Ms1 cells. (F) anti-TeM1 scFv-armed NPs treated TeM1-positive Ms1 
cells. Green color represents fluorescein-loaded PLGA NPs. (G–I), respectively, represent light microscopy, fluorescence microscopy, and light microscopy–fluorescence 
microscopy superimposed images of anti-TeM1 scFv-armed NPs treated TeM1-positive Ms1 cells. Phalloidin–tetramethylrhodamine B isothiocyanate was used to stain the 
cytoplasmic F-actin (red). 4′,6-diamidino-2-phenylindole was used to stain the nucleus (blue).
Abbreviations: ab, antibody; NPs, nanoparticles; Plga, poly(lactic-co-glycolic acid); scFv, single-chain variable fragment; TeM1, tumor endothelial marker 1.
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Figure 6 Fluorescence microscopy (FM) images of free shikonin (shK) effects in 
OVcar-5 cells.
Notes: (A) FM image of the untreated cells. (B) stylized image of the untreated 
cells. (C) FM image of the treated cells with 5.0 µM shK. (D) stylized image of the 
treated cells with 10.0 µM shK. (E) FM image of the treated cells with 20 µM shK. 
(F) stylized image of the treated cells with 20.0 µM shK.
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because of the cytotoxic nature of most anticancer chemothera-
peutic agents. To overcome such problems, a large number 
of investigators have attempted to deliver chemotherapeutics 
exclusively to the target cancerous cells within the TME. As 
the tumor microvasculature displays a disordered fenestrated 
endothelial architecture, the nanomedicines can be accumu-
lated within the TME based upon the EPR effect (so-called 
“passive targeting”). Such nanomedicines can be further armed 
with homing devices to exploit “active targeting” mechanisms 
as well.30 So far, various drug delivery systems have been used 
in engineering nanoscale formulations for delivery of cytotoxic 
agents. In comparison with toxic non-biodegradable  polymer-/
lipid-based drug delivery systems,22,31–34 biodegradable poly-
mers such as PLGA appear to be a safer biocompatible system 
for delivery of anticancer agents.17,19,21 In the current study, 
we capitalized on the engineering of Ab-armed PEGylated 
PLGA NPs for delivery of SHK, which is known as cytostatic, 
cytotoxic and immunomodulatory secondary metabolite in a 
concentration-dependent manner.10,11 SHK can effectively acti-
vate both receptor- and mitochondria-mediated apoptosis7 and 
circumvent cancer drug resistance by induction of a necroptotic 
death.35 In order to induce specific cytotoxic impacts solely in 
cancer cells within the TME, we aimed to harness both passive 
and active targeting mechanisms by engineering SHK-loaded 
PLGA NPs armed with TEM1-targeting Ab/scFv.
Depending on the composition and method used (ie, 
polymer and surfactant type and concentration, sonication), 
as described previously,36 we found that the engineered 
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PLGA NPs showed a size range of 150–250 nm (Figure 2) 
and a smooth surface (Figure 3). Among several formulations 
examined, PLGA (50:50 with Mw of 38,000–54,000 
[3% w/v]) and Pluronic® F68 (3% w/v) provided NPs at a 
size range of ∼200 nm with a sound distribution pattern and 
high DE% (∼90%).
The release of SHK from PLGA NPs was studied at dif-
ferent pHs to reveal the pattern of releases within the vesicular 
machineries of the target cells as well as the TME, in which 
the pH is acidic. We found slower release at lower pH (Figure 
4), which indicates sustained release of SHK in acidic condi-
tions, resulting in longer presence of drug molecules at the 
TME. To disclose the drug release kinetics, the release data 
were fit using several models (Table 2), as described previous-
ly.26 The release data were best fit with Wagner log-probability 
and, to some extent, with Weibull models (Table 2), which 
is in consensus with a previous report on the release of lipo-
philic drugs from polymeric NPs.26 We assumed that these 
NPs can reach the target tumor site within 2 hours,37,38 during 
which period the liberation of SHK (∼20%) can favor the 
cancer therapy objectives by activating the immune system.9 
Once these NPs reached into the TME by EPR effect, they 
could attach to the tumor endothelial cells through homing 
devices (targeting TEM1) and accumulate within the TME 
where SHK is released (.80%) within 24–48 hours. Such 
accumulation of SHK within the TME can induce maximum 
cytotoxic effects. It should be noted that the plain PLGA NPs 
are inherently prone to opsonization and reticuloendothelial 
system clearance.39,40 To avoid such problems, the PLGA NPs 
have been PEGylated to become invisible to the immune sys-
tem and to enhance the EPR effect.39,41 For active and specific 
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targeting of cancer cells in the current study, the PLGA NPs 
were PEGylated and further conjugated with anti-TEM1 Ab/
scFv using EDC/NHS chemistry (Figure 1). We found that a 
20:1 molar ratio of homing device:PEG provided NPs with 
significant potential to bind to the TEM1 that is overexpressed 
in tumor vasculature endothelia. The anti-TEM1 Ab/scFv-
armed  PEGylated PLGA NPs were significantly able to bind 
the TEM1-positive MS1 cells, but not the TEM1-negative 
MS1 cells (Figure 5). We found that the binding potential 
of the scFv-armed NPs was significantly greater than the 
Ab-armed NPs, perhaps due to the smaller size and mass of 
the scFv that allow a higher level of conjugation compared 
to the whole Ab. It should be stated that the surface decora-
tion of the PLGA NPs was associated with some drug loss 
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(Table 1), which was taken into account for cytotoxicity 
studies. The two-step post-formulation surface modification 
processes of PEGylation and Ab/scFv  conjugation resulted 
in greater loss of SHK.
Since the main objective of the study was to specifically 
deliver SHK to, and investigate its impacts in the target 
cells, we first compared the morphological changes of the 
OVCAR-5 cells treated with SHK using fluorescence micros-
copy. Morphological evaluation showed that SHK induced 
profound morphological changes in ovarian cancer OVCAR-5 
cells (Figure 6). We found that the SHK-treated cells showed 
somewhat lower phalloidin staining, especially regarding the 
formation of lamellipodial ruffling.42 This emphasizes the 
impact of SHK on cell motility and migration capacity, which 
was further confirmed by cell migration assay (Figure 7). 
Based on morphological changes, it seems SHK can induce 
chromatin condensation and nuclear shrinkage. These find-
ings are in consensus with reported effects of SHK on C6 
glioma cells;43 nonetheless, the genomic and/or epigenomic 
impacts of SHK are yet to be fully investigated. Huang et al, 
in 2013, demonstrated that SHK can elicit cell death mainly 
via necroptosis mechanism,43 which is in full agreement with 
our results in both OVCAR-5 and MS1 cells.
The SRB cytotoxic assay revealed that free SHK can 
induce toxicity in the ovarian cancer OVCAR-5 cells as well 
as in the normal ovarian IOSE-398 cells and Jurkat cells 
(Figure 8). Such nonspecific toxicity further highlighted the 
inevitability of specific delivery of SHK to the TME through 
passive and active targeting mechanisms in order to diminish 
the nonspecific side effects. Thus, to exploit both passive 
and active targeting potentials, we engineered SHK-loaded 
PEGylated PLGA NPs decorated with anti-TEM1 Ab/scFv. 
TEM1 has been reported to be expressed by the endothelial 
cells of ovarian tumor vasculature25,44–47 and other malignan-
cies such as brain and abdominal tumors.48,49 Based on the 
release profile, less than 20% of drug can be released within 
2 hours, during which the engineered NPs can safely pass 
the blood stream and reach the target site with negligible 
inadvertent detrimental impacts on blood-circulating immune 
system cells. To this end, the toxic effects of SHK-loaded 
NPs were tested in primary lymphocytes and it was found 
that the SHK-loaded PEGylated NPs were significantly safer 
than non-PEGylated NPs (Figure 9). To evaluate the effect of 
anti-TEM1 Ab/scFv-armed SHK-loaded PLGA NPs, we used 
TEM1-negative MS1 cells and human TEM1-transfected 
MS1 cells. In accordance with the fluorescence microscopy 
results (Figure 5), we found that the anti-TEM1 Ab/scFv-
armed SHK-loaded PLGA NPs could induce significantly 
greater toxicity in TEM1-positive MS1 endothelial cells 
(Figure 10). These findings may verify our primary assump-
tion that the active targeting of TEM1 could enhance the 
EPR effect through binding to the TEM1-expressing tumor 
endothelial cells during circulation in blood. We speculate 
that, once attached to the tumor vasculature, these NPs are 
entrapped and accumulated solely within the tumor site. 
Our findings confirmed that decoration of PLGA NPs with 
anti-TEM1 scFv provides higher antigen-binding capacity as 
compared to the PLGA NPs conjugated with anti-TEM1 Ab 
(Figures 5 and 10). The results of the SRB toxicity assay were 
further confirmed using flow cytometry apoptosis/necrosis 
assay (Figure 10E and F). Our results are in accordance 
with previous reports showing that SHK can induce both 
apoptosis and necrosis in cancer cells.50–52 Further, given that 
annexin V is not cell permeable, the binding of externalized 
phosphatidylserine (PS) is selective for early apoptotic cells, 
hence we aimed to discriminate the stage of apoptosis that 
occurred in the cells treated with free SHK or SHK-loaded 
Figure 12 effect of shikonin on DNa defragmentation in OVcar-5 cells.
Notes: lanes 1–4 represent untreated control cells and shikonin (2.5, 5.0, and 
10.0 µM)-treated cells, respectively.
Abbreviation: MWl, molecular weight ladder.
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NPs. Using TEM1-positive MS1 cells (with 95% expression 
of TEM1) and TEM1-negative MS1 cells, we found that 
Ab- or scFv-armed PLGA NPs loaded with SHK were able 
to induce significantly (P,0.05) greater cytotoxic impacts 
in TEM1-positive MS1 cells than in TEM1-negative MS1 
cells (Figure 10A and B). Further, the impact of unarmed NPs 
encapsulating SHK was greater than that of the free SHK, 
showing the potential of passive targeting. Our preliminary 
confocal microscopy showed that the engineered SHK-loaded 
NPs can be taken up by the epithelial cancerous cells (data 
not shown) and induce profound toxicity in a dose-dependent 
manner as shown for the OVCAR-5 cells (Figure 11). Based 
on the flow cytometry analysis, SHK-treated cells showed 
both apoptosis and necrosis after 6 hours (Figure 10C–F), 
while they became mainly necrotic after 24 hours, which was 
further confirmed by DNA fragmentation assay (Figure 12). 
In fact, SHK is a naturally occurring naphthoquinone with 
profound inhibitory effects on cancer cell proliferation both 
in vivo and in vitro.6,53 Chen et al reported in 2012 that SHK 
can induce generation of reactive oxygen species, depletion 
of glutathione, disruption of mitochondrial transmembrane 
potential, upregulation of p53, cleavage of poly(adenosine 
diphosphate [ADP]-ribose) polymerase, catalase downregu-
lation, super oxide dismutases (SOD1) upregulation, BCL2 
downregulation, and BAX upregulation in U87MG glioma 
cells.6 In human glioma cells, SHK-induced necroptosis 
appears to occur through multiple pathways, while it has also 
been shown to inhibit the glycolytic path in cancers through 
inhibiting pyruvate kinase-M2 (PKM2).13 Similarly, skin 
epidermal JB6 P+ cells treated with SHK showed marked 
induction of apoptosis through suppression of PKM2 activa-
tion, and decreased level of lactate as a glycolysis marker, 
thus mitochondrial dysfunction.12 In summary, SHK can 
induce necroptosis through multiple pathways, such as by 
inhibiting the activity of PKM2. Thus, if SHK is specifically 
delivered to cancer cells using targeted nanomedicines, it can 
result in significant suppression of dysregulated molecular 
events within the TME.
Conclusion
SHK is able to induce marked cytotoxic impacts in ovarian 
cancer cells. However, similar to other cytotoxic agents, such 
as doxorubicin, its toxic impact is nonspecific, resulting in 
inadvertent detrimental impact on normal cells. Based on 
our findings, we propose biodegradable SHK-loaded PLGA 
NPs PEGylated and armed with anti-TEM1 scFv as a new 
targeted nanomedicine for ovarian cancer therapy as well as 
for other solid tumors.
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